Who is sponsoring NCT03237715?

NCT03237715 is sponsored by Rutgers University.

What drugs are being tested in NCT03237715?

Interventions in NCT03237715: Assessment of unbound bilirubin levels.

What condition does NCT03237715 study?

NCT03237715 studies Neonatal Jaundice.

Is NCT03237715 still recruiting?

NCT03237715 is currently status unknown. Last updated 2 August 2017.

Last reviewed 2017-08-02 · How we verify

NCT03237715

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Unbound Bilirubin Levels in Healthy Term and Late Preterm Infants

Status unknown Last updated 2 August 2017

What this trial tests

trial testing Assessment of unbound bilirubin levels in Neonatal Jaundice in 180 participants. Status unknown.

Timeline

1 July 2017

Primary endpoint
30 June 2019

30 June 2019

Quick facts

Lead sponsor	Rutgers University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	180
Start date	1 July 2017
Primary completion	30 June 2019
Estimated completion	30 June 2019
Sites	1 location across United States

Drugs / interventions tested

Assessment of unbound bilirubin levels

Conditions studied

Neonatal Jaundice — all drugs for Neonatal Jaundice →

Sponsor

Rutgers University

Who can join

Adults 6 Hours to 7 Days, any sex, with Neonatal Jaundice. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Specific Aim 1: To determine total serum bilirubin (TSB) and unbound bilirubin (Bf) levels in term and late preterm infants during the first week of life. Specific Aim 2: Measure Bf levels in breast fed and formula fed infants and examine their relationship to unbound fatty acid (FFAu) levels. Specific Aim 3: To demonstrate that phototherapy results in different changes in TSB and Bf.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neonatal Jaundice

Currently open trials in the same condition.

NCT06963450 — NeoSCB App for Screening Jaundice in Newborns · recruiting
NCT06399146 — Evaluation of Bilirubin Estimates in Newborns From Smartphone Digital Images in a Population in Botswana · NA · recruiting
NCT05521607 — Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice (Chicago) · NA · recruiting

Other Rutgers University trials

Trials by the same sponsor.

NCT04868123 — Effects of TENS and Mindfulness Meditation in Persons With HIV-related Neuropathy · NA · completed
NCT04563728 — Use Surveillance Technology to Reduce Elder Abuse Recidivism · NA · terminated
NCT04432493 — Using Combined EEG and Non-invasive Brain Stimulation to Examine and Improve Reward Functioning in Opioid Use Disorder · NA · completed
NCT04107688 — Taste Perception, Salivary Proteins & the Oral Microbiome · NA · completed
NCT03672266 — Studies of Brain and Body Interaction · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03237715 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rutgers University
Last refreshed: 2 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03237715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing